<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="369725">
  <stage>Registered</stage>
  <submitdate>3/12/2015</submitdate>
  <approvaldate>3/02/2016</approvaldate>
  <actrnumber>ACTRN12616000124437p</actrnumber>
  <trial_identification>
    <studytitle>Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, clinical trial in children in Sri Lanka, 2016</studytitle>
    <scientifictitle>Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, a randomized clinical trial in 300 children aged 10-12 years of age living in Kalutara district of Sri Lanka, 2016
</scientifictitle>
    <utrn>U1111-1177-2137 </utrn>
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>poliomyelitis</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Full one dose (0.5 ml) of inactivated poliovirus vaccine administered intramuscularly
or
Fractional one dose (0.1 ml) of inactivated poliovirus vaccine administered intradermally</interventions>
    <comparator>no vaccine administered in the control group</comparator>
    <control>Active</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Difference in proportion of children excreting vaccine polioviruses (by serotype) between arms among those who serologically respond to IPV measured by isolation of poliovirus in stool</outcome>
      <timepoint>7 days after administration of live oral poliovirus vaccine</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Difference in duration of poliovirus excretion between arms measured by isolation of poliovirus in stool</outcome>
      <timepoint>42 days after challenge with oral poliovirus vaccine</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Any child 10-12 years of age residing in the determined area of Kalutara
Parent/Guardian provides consent for childs participation, including vaccination with IPV/OPV and blood and stool sample collections
</inclusivecriteria>
    <inclusiveminage>10</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>12</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Contraindication for venepuncture
Sick child requiring hospitalization for acute or chronic condition
Diagnosis or suspicion of congenital immunodeficiency disorder in the subject or an immediate family member
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>15/02/2016</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>300</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Sri Lanka</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>World Health Organization</primarysponsorname>
    <primarysponsoraddress>Avenue Appia 20
CH-1211 Geneva 27 Switzerland
</primarysponsoraddress>
    <primarysponsorcountry>Switzerland</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>World Health Organisation</fundingname>
      <fundingaddress>Avenue Appia 20
CH-1211 Geneva 27 Suisse
</fundingaddress>
      <fundingcountry>Switzerland</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>none</sponsorname>
      <sponsoraddress>none</sponsoraddress>
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will evaluate the effect of fIPV on boosting mucosal immunity against polioviruses in Sri Lanka, a country with high routine immunization coverage with OPV and IPV introduced in its routine immunization schedule. It will enable decision makers in Sri Lanka as well as in other countries in similar situation, to evaluate risks and benefits of fIPV use for OBR in case of cVDPV2 outbreak following the tOPV to bOPV switch.

After April 2016, no country will be allowed to use tOPV therefore this is a last chance to conduct this type of a study and all study procedures must be completed by the end of April 2016.
</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Submitted, not yet approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>World Health Organisation</ethicname>
      <ethicaddress>Avenue Appia 20
CH-1211 Geneva 27 Suisse
</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>1/12/2015</ethicsubmitdate>
      <ethiccountry>Switzerland</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Paba Palihawadana</name>
      <address>Epidemiology Unit , Ministry of Health,Sri Lanka.
231, De Saram Road, Colombo 10
</address>
      <phone>+94-112 695 112</phone>
      <fax />
      <email>paba@health.gov.lk</email>
      <country>Sri Lanka</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Ondrej Mach</name>
      <address>World Health Organization
Avenue Appia 20
CH-1211 Geneva 27 Suisse
</address>
      <phone>+41227911863</phone>
      <fax />
      <email>macho@who.int</email>
      <country>Switzerland</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>ondrej mach</name>
      <address>World Health Organization
Avenue Appia 20
CH-1211 Geneva 27 Suisse
</address>
      <phone>+41227911863</phone>
      <fax />
      <email>macho@who.int</email>
      <country>Switzerland</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>